LPL Receptor
Lysophospholipid Receptor
LPL Receptor (Lysophospholipid Receptor) group are members of the G protein-coupled receptor family of integral membrane proteins that are important for lipid signaling. In humans, there are eight LPL receptors, each encoded by a separate gene. These LPL receptor genes are also sometimes referred to as "Edg". LPL receptor ligands bind to and activate their cognate receptors located in the cell membrane. Depending on which ligand, receptor, and cell type is involved, the activated receptor can have a range of effects on the cell. These include primary effects of inhibition of adenylyl cyclase and release of calcium from the endoplasmic reticulum, as well as secondary effects of preventingapoptosis and increasing cell proliferation. Type: LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, LPAR6, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5.
LPL Receptor Isoform Specific Products
All Product Categories
-
LPL Receptor Inhibitors
(66)
View all products
-
LPL Receptor Agonists
(93)
View all products
-
LPL Receptor Antagonists
(68)
View all products
-
LPL Receptor Activators
(16)
View all products
-
LPL Receptor Modulators
(18)
View all products
-
LPL Receptor Control
(1)
View all products
-
LPL Receptor Ligand
(1)
View all products
-
LPL Receptor Related Products (279)
Related Products (279)
-
Antibodies (7)
-
LPL Receptor Isoform Comparison
-
Fingolimod phosphate-d4
0 ImagesCat. No.: HY-15381SCAS No.: 1794828-93-5Synonyms: FTY720 phosphate-d4Fingolimod phosphate-d4 is deuterium labeled FTY720 Phosphate.
-
Glycocholic acid sodium (Standard)
0 ImagesCat. No.: HY-N1423ARCAS No.: 863-57-0Glycocholic acid (sodium) (Standard) is the analytical standard of Glycocholic acid sodium (HY-N1423A). This product is intended for research and analytical applications. Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
-
pro-FTY
0 ImagesCat. No.: HY-175201CAS No.: 3064707-13-4pro-FTY, a FTY720 (HY-12005) anticancer prodrug, is a sphingosine-1-phosphate (S1P) (HY-108496) inhibitor. pro-FTY specifically inhibits S1P signaling in cancer cells using a drug delivery system (DDS) that reacts with acrolein. pro-FTY significantly inhibits the survival of breast cancer cells, including multidrug-resistant cells and its organoids resistant to Paclitaxel (HY-B0015) or Doxorubicin (HY-15142A). pro-FTY potently suppresses tumor growth in 4T1 cells or organoids xenograft tumors mice model while avoiding lymphocytopenia.
-
LPAR1 antagonist 2
0 ImagesCat. No.: HY-160661CAS No.: 1664336-46-2LPAR1 antagonist 2 (example 76) is an LPAR1 antagonist with an average IC50 of 130 nM.
-
Obicetrapib sodium
0 ImagesCat. No.: HY-18778ACAS No.: 866399-88-4Synonyms: TA-8995 sodium; DEZ-001 sodium; AMG-899 sodiumObicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
-
(Rac)-1-Oleoyl lysophosphatidic acid
0 ImagesCat. No.: HY-137862ACAS No.: 22002-87-5Synonyms: (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the LPA receptors .
-
XL541
0 ImagesCat. No.: HY-18165CAS No.: 1221878-06-3XL541 is a potent, selective S1P1 antagonist. XL541 inhibits GDP-GTP exchange. XL541 causes frank surface hemorrhaging of tumors. XL541 collaborates with Paclitaxel (HY-B0015) to exhibit antitumor activity against breast cancer and lung cancer.
-
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium
0 ImagesCat. No.: HY-171906ASynonyms: 1-Arachidonoyl-sn-glycerol 3-phosphate sodium; 1-Arachidonoyl LPA sodium; LPA (20:4) sodium1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) (1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)) is a phospholipid with arachifonic acid at the sn-1 position. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) binds to the LPA2/EDG4 receptor (EC50 of 10 nM). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can be found in rat brain as 37% of the arachidoinic acid-containing lysophosphatidic acid species. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) is the precursor to 1-arachidonoyl glycerol. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can prevent TNF-α and IL-6 secretion in wild type LPS-stimulated dendritic cells. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) reduces differentiation of HT-29 colon carcinoma cells into goblet cells when sodium butyrate is present.
-
BrP-LPA
0 ImagesCat. No.: HY-W725737CAS No.: 944313-05-7BrP-LPA is a LPA antagonist/ATX inhibitor. BrP-LPA shows pan-antagonist activity towards LPA1-4 GPCRs. BrP-LPA decreases blood vessel density. BrP-LPA dose-dependently inhibits Lysophosphatidic acid-induced head-dip counts. BrP-LPA exhibits anticancer activity against breast cancer, colon cancer, and lung cancer. BrP-LPA inhibits anxiety-like behavior.
-
(R)-SLB1122168 free base
0 ImagesCat. No.: HY-182375CAS No.: 2764877-97-4(R)-SLB1122168 free base, an isomer of SLB1122168 free base (HY-182375A), is a spinster homolog 2 (SPNS2) inhibitor with an IC50 ≤2 μM.
-
BMT-136088
0 ImagesCat. No.: HY-171806CAS No.: 1257213-96-9BMT-136088 is a LPAR1 antagonist. 11C-BMT-136088 can be used as a positron emission tomography (PET) radioligand to quantify specific binding to LPA1 in lung.
-
S1P2 antagonist 1
0 ImagesCat. No.: HY-141845CAS No.: 2262402-83-3S1P2 antagonist 1 is an orally bioavailable S1P2 antagonist against fibrotic diseases.
-
CS1P1
0 ImagesCat. No.: HY-182626CAS No.: 1246526-29-3CS1P1 is a brain-penetrant and selective S1PR1 antagonist and PET radiotracer, with human S1PR1 IC50 values of 2.1 nM. CS1P1 binds specifically to S1PR1 to enable in vivo receptor expression quantification. CS1P1 can be used as PET radiotracer when labelled with 11C. CS1P1 can be used for the research of multiple sclerosis, neointimal hyperplasia, vascular inflammation.
-
Fingolimod hydrochloride (Standard)
0 ImagesSynonyms: FTY720 (Standard)Fingolimod (hydrochloride) (Standard) is the analytical standard of Fingolimod (hydrochloride). This product is intended for research and analytical applications. Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator.
-
L-NASPA ammonium
0 ImagesCat. No.: HY-W040175CAS No.: 799268-44-3L-NASPA ammonium is a ophosphatidic acid (LPA) inhibitor useful in the study of platelet activation.
-
Spns2-IN-3
0 ImagesCat. No.: HY-176500CAS No.: 3035022-30-8Sphingolipid E is a synthetic pseudoceramide sphingolipid similar to type 2 ceramide with a metastable lamellar structure. Sphingolipid E ??can be used as a potential drug carrier to control the penetration of molecules as a lipid component of the intercellular space of the stratum corneum.
-
(R)-VPC44116
0 ImagesCat. No.: HY-117892ACAS No.: 925978-30-9(R)-VPC44116 is an isomer of VPC44116. VPC44116 is a selective S1P1 receptor antagonist.
-
BMS-986020 sodium (Standard)
0 ImagesCat. No.: HY-100619ARCAS No.: 1380650-53-2Synonyms: AM152 sodium (Standard)BMS-986020 (sodium) (Standard) is the analytical standard of BMS-986020 (sodium) (HY-100619A). This product is intended for research and analytical applications. BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
